#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

Af­ter kick­ing off a mul­ti­ple myelo­ma ri­val­ry with Bris­tol My­ers Squibb at last year’s ASH, Re­gen­eron is back with an up­dat­ed safe­ty and dura­bil­i­ty analy­sis from the first-in-hu­man study of its BC­MA bis­pe­cif­ic.

In the Phase I por­tion of a Phase I/II dose-es­ca­la­tion study, re­searchers not­ed a 6-month me­di­an du­ra­tion of re­sponse, Re­gen­eron an­nounced at ASH 2020. “We feel very en­cour­aged,” An­dres Sir­ul­nik, se­nior VP of trans­la­tion­al and clin­i­cal sci­ences and hema­tol­ogy, said of REGN5458. The drug is very well tol­er­at­ed.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.